Angioarchitectural Determinants of Limb Loss After Endovascular Treatment in Patients with Diabetic Foot Syndrome and Coronary Artery Disease
DOI:
https://doi.org/10.55640/ijmm-05-02-05Keywords:
Diabetic foot syndrome, peripheral arterial disease, endovascular treatmentAbstract
Background: Diabetic foot syndrome (DFS) combined with ischemic heart disease (IHD) represents a high-risk vascular condition frequently requiring endovascular revascularization. However, clinical outcomes remain heterogeneous, particularly in the presence of diffuse arterial disease.
Objective: To evaluate angioarchitectural and procedural determinants of limb loss after endovascular treatment in patients with DFS and concomitant IHD.
Methods: A retrospective single-center study included 58 patients with DFS and IHD who underwent endovascular intervention between 2015 and 2019. Patients were stratified according to clinical outcome into favorable and unfavorable groups. Angiographic parameters analyzed included number of affected arterial segments, level of involvement, vascular access strategy, and type of intervention (balloon angioplasty alone or combined with stenting). Primary endpoint was major amputation. Secondary endpoints included procedural complications and early mortality.
Results: Unfavorable outcomes occurred in 37.9% of patients. Multi-segment arterial involvement (≥2 segments), extensive disease affecting ≥3 segments, and crossover vascular access were significantly more frequent in the unfavorable group (p <0.01). Combined balloon angioplasty with stenting was required more often in these patients (59.1% vs 33.3%, p <0.05). Stent occlusion, thrombosis, and early restenosis were associated with higher amputation rates. Major amputation occurred in 45.4% of patients with unfavorable outcomes, while early mortality reached 13.6%.
Conclusion: Diffuse angioarchitectural involvement and procedural complexity are strongly associated with limb loss after endovascular treatment in patients with DFS and IHD. Incorporating anatomical severity into preprocedural assessment may improve risk stratification and limb salvage strategies.
Downloads
References
Burke A.P., Kolodgie F.D., Zieske A. et al. Morphologic findings in coronary atherosclerosis in diabetes mellitus: a postmortem study // Arterioscler Thromb Vasc Biol. – 2016. – Vol. 24, No. 7. – P. 1266–1271
Armstrong D.G., Boulton A.J.M., Bus S.A. et al. Five-year mortality and direct costs of care for people with diabetic foot complications // Diabetologia. – 2020. – Т. 63, № 5. – С. 1035–1045.
Wild S.H., Byrne C.D. Risk factors for cardiovascular disease in type 2 diabetes // Diabet Med. – 2017. – Vol. 33, No. 3. – P. 290–297
Shamsiev A.A., Atakov A.A., Tadjikhodjaeva M.R. et al. Diabetes in Uzbekistan: challenges and solutions // International Journal of Diabetes in Developing Countries. – 2020. – Т. 40, № 1. – С. 102–108.
Narayan K.V., Gregg E.W., Fowkes F.G.R. et al. Peripheral artery disease in diabetes: the complex interplay of inflammation and ischemia // Diabetes Care. – 2021. – Т. 44, № 3. – С. 651–660.
Zhou B., Bentham J., Di Cesare M. et al. Worldwide trends in diabetes since 1980: a pooled analysis // Lancet. – 2016. – Т. 387, № 10027. – С. 1513–1530.
Yazdan-Ashoori P., Baranchuk A., Redfearn D. et al. Diabetic foot ulcers and cardiovascular disease: a deadly combination // Canadian Journal of Diabetes. – 2017. – Т. 41, № 1. – С. 88–94.
Wingard D.L., Barrett-Connor E., Ferrara A. Is insulin really a cardiovascular risk factor? Diabetes Care. – 2017. – Vol. 40, No. 5. – P. 598–604
Timoteo A.T., Rosário I., Fiarresga A. et al. Diabetes is associated with more extensive, severe, and diffuse coronary artery disease // Cardiovasc Diabetol. – 2020. – Vol. 19, No. 1. – P. 106
Mozaffarian D., Benjamin E.J., Go A.S. et al. Executive Summary: Heart Disease and Stroke Statistics — 2016 Update // Circulation. – 2016. – Т. 133. – С. 447–454.
Downloads
Published
Issue
Section
License
Copyright (c) 2026 Kamolov S.T., Zufarov M.M. (Author)
This work is licensed under a Creative Commons Attribution 4.0 International License.
